Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Daniel Kuritzkes
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Living Beings
Disorders
Chemicals & Drugs
Physiology
Procedures
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
30
Johnson, Victoria
22
D'Aquila, Richard
21
Richman, Douglas
17
Clotet, Bonaventura
17
Gulick, Roy
16
Eron, Joseph
14
Landay, Alan
13
Connick, Elizabeth
12
Lederman, Michael
12
Pillay, Deenan
12
Ribaudo, Heather
11
Brun-Vézinet, Françoise
11
Acosta, Edward
10
DeGruttola, Victor
10
Hammer, Scott
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Daniel Kuritzkes (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Su Zhaohui; Gulick Roy M; Krambrink Amy; Coakley Eoin; Hughes Michael D; Han Dong; Flexner Charles; Wilkin Timothy J; Skolnik Paul R; Greaves Wayne L; Kuritzkes Daniel R; Reeves Jacqueline D;
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.
The Journal of infectious diseases 2009;200(11):1724-8.
-
2009: Kim Yun-Gon; Moon Sangjun; Kuritzkes Daniel R; Demirci Utkan
Quantum dot-based HIV capture and imaging in a microfluidic channel.
Biosensors & bioelectronics 2009;25(1):253-8.
-
2009: Hosoya Noriaki; Su Zhaohui; Wilkin Timothy; Gulick Roy M; Flexner Charles; Hughes Michael D; Skolnik Paul R; Giguel Françoise; Greaves Wayne L; Coakley Eoin; Kuritzkes Daniel R
Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions.
Journal of clinical microbiology 2009;47(8):2604-6.
-
2009: Kuritzkes Daniel R
Interleukin-2: trials and tribulations.
The Journal of infectious diseases 2009;200(2):164-5.
-
2009: Moore John P; Kuritzkes Daniel R
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
Current opinion in HIV and AIDS 2009;4(2):118-24.
-
2009: Kuritzkes Daniel R
HIV-1 entry inhibitors: an overview.
Current opinion in HIV and AIDS 2009;4(2):82-7.
-
2009: Tsibris Athe M N; Paredes Roger; Chadburn Amy; Su Zhaohui; Henrich Timothy J; Krambrink Amy; Hughes Michael D; Aberg Judith A; Currier Judith S; Tashima Karen; Godfrey Catherine; Greaves Wayne; Flexner Charles; Skolnik Paul R; Wilkin Timothy J; Gulick Roy M; Kuritzkes Daniel R
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(5):642-9.
-
2009: Tenorio Allan R; Jiang Hongyu; Zheng Yu; Bastow Barbara; Kuritzkes Daniel R; Bartlett John A; Deeks Steven G; Landay Alan L; Riddler Sharon A
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.
AIDS research and human retroviruses 2009;25(2):135-9.
-
2009: Paredes Roger; Sagar Manish; Marconi Vincent C; Hoh Rebecca; Martin Jeffrey N; Parkin Neil T; Petropoulos Christos J; Deeks Steven G; Kuritzkes Daniel R
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.
Journal of virology 2009;83(4):2038-43.
-
2009: Jacobson Jeffrey M; Kuritzkes Daniel R; Godofsky Eliot; DeJesus Edwin; Larson Jeffrey A; Weinheimer Steven P; Lewis Stanley T
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
Antimicrobial agents and chemotherapy 2009;53(2):450-7.
-
2009: Murphy Richard A; France Holly; Sunpath Henry; Gordon Michelle L; Marconi Vincent C; Kuritzkes Daniel R; McIntosh Kenneth
Development of dual-class antiretroviral drug resistance in a child coinfected with HIV and tuberculosis: a case report from KwaZulu-Natal, South Africa.
Journal of tropical pediatrics 2009;55(1):60-2.
-
2009: Kuritzkes Daniel R
Drug Therapy in HIV Infection--Ninth International Congress.
IDrugs : the investigational drugs journal 2009;12(1):20-5.
-
2009: Tsibris Athe M N; Korber Bette; Arnaout Ramy; Russ Carsten; Lo Chien-Chi; Leitner Thomas; Gaschen Brian; Theiler James; Paredes Roger; Su Zhaohui; Hughes Michael D; Gulick Roy M; Greaves Wayne; Coakley Eoin; Flexner Charles; Nusbaum Chad; Kuritzkes Daniel R
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.
PloS one 2009;4(5):e5683.
-
2009: Bennett Diane E; Camacho Ricardo J; Otelea Dan; Kuritzkes Daniel R; Fleury Hervé; Kiuchi Mark; Heneine Walid; Kantor Rami; Jordan Michael R; Schapiro Jonathan M; Vandamme Anne-Mieke; Sandstrom Paul; Boucher Charles A B; van de Vijver David; Rhee Soo-Yon; Liu Tommy F; Pillay Deenan; Shafer Robert W
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
PloS one 2009;4(3):e4724.
-
2008: Hirsch Martin S; Günthard Huldrych F; Schapiro Jonathan M; Brun-Vézinet Françoise; Clotet Bonaventura; Hammer Scott M; Johnson Victoria A; Kuritzkes Daniel R; Mellors John W; Pillay Deenan; Yeni Patrick G; Jacobsen Donna M; Richman Douglas D;
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(3):266-85.
-
2008: Kuritzkes Daniel R
Report from the XVII International HIV Drug Resistance Workshop.
AIDS clinical care 2008;20(8):61-2.
-
2008: Marconi Vincent; Bonhoeffer Sebastian; Paredes Roger; Lu Jing; Hoh Rebecca; Martin Jeffery N; Deeks Steven G; Kuritzkes Daniel R
Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.
Journal of acquired immune deficiency syndromes (1999) 2008;48(5):572-6.
-
2008: Tsibris Athe M N; Sagar Manish; Gulick Roy M; Su Zhaohui; Hughes Michael; Greaves Wayne; Subramanian Mani; Flexner Charles; Giguel Françoise; Leopold Kay E; Coakley Eoin; Kuritzkes Daniel R
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
Journal of virology 2008;82(16):8210-4.
-
2008: Hirsch Martin S; Günthard Huldrych F; Schapiro Jonathan M; Brun-Vézinet Françoise; Clotet Bonaventura; Hammer Scott M; Johnson Victoria A; Kuritzkes Daniel R; Mellors John W; Pillay Deenan; Yeni Patrick G; Jacobsen Donna M; Richman Douglas D
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(2):266-85.
-
2008: Marconi Vincent C; Sunpath Henry; Lu Zhigang; Gordon Michelle; Koranteng-Apeagyei Kofi; Hampton Jane; Carpenter Steve; Giddy Janet; Ross Douglas; Holst Helga; Losina Elena; Walker Bruce D; Kuritzkes Daniel R;
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(10):1589-97.
-
2008: Ribaudo Heather J; Kuritzkes Daniel R; Lalama Christina M; Schouten Jeffrey T; Schackman Bruce R; Acosta Edward P; Gulick Roy M
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
The Journal of infectious diseases 2008;197(7):1006-10.
-
2008: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Gunthard Huldrych F; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Richman Douglas D
Update of the Drug Resistance Mutations in HIV-1: Spring 2008.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(1):62-8.
-
2008: Kuritzkes Daniel R; Lalama Christina M; Ribaudo Heather J; Marcial Michelle; Meyer William A; Shikuma Cecilia; Johnson Victoria A; Fiscus Susan A; D'Aquila Richard T; Schackman Bruce R; Acosta Edward P; Gulick Roy M
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
The Journal of infectious diseases 2008;197(6):867-70.
-
2008: Kuritzkes Daniel R
HIV-1 subtype as a determinant of disease progression.
The Journal of infectious diseases 2008;197(5):638-9.
-
2008: Price Richard W; Parham Robin; Kroll Jing Lu; Wring Stephen A; Baker Brian; Sailstad Jeff; Hoh Rebecca; Liegler Teri; Spudich Serena; Kuritzkes Daniel R; Deeks Steven G
Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
Antiviral therapy 2008;13(3):369-74.
-
2007: Schackman Bruce R; Ribaudo Heather J; Krambrink Amy; Hughes Valery; Kuritzkes Daniel R; Gulick Roy M
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
Journal of acquired immune deficiency syndromes (1999) 2007;46(5):547-54.
-
2007: Murphy Richard A; Sunpath Henry; Kuritzkes Daniel R; Venter Francois; Gandhi Rajesh T
Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.
The Journal of infectious diseases 2007;196 Suppl 3():S449-56.
-
2007: Paredes Roger; Marconi Vincent C; Campbell Thomas B; Kuritzkes Daniel R
Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.
Journal of virological methods 2007;146(1-2):136-46.
-
2007: Wester C William; Okezie Okechukwu A; Thomas Ann Muir; Bussmann Hermann; Moyo Sikhulile; Muzenda Tanaka; Makhema Joseph; van Widenfelt Erik; Musonda Rosemary; Novitsky Vladimir; Gaolathe Tendani; Ndwapi Ndwapi; Essex Max; Kuritzkes Daniel R; DeGruttola Victor; Marlink Richard G
Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.
Journal of acquired immune deficiency syndromes (1999) 2007;46(3):318-22.
-
2007: Kuritzkes Daniel R
HIV resistance: frequency, testing, mechanisms.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2007;15(5):150-4.
-
2007: Paredes Roger; Cheng Irene; Kuritzkes Daniel R; Tuomala Ruth E
High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.
AIDS (London, England) 2007;21(15):2103-6.
-
2007: Ribaudo Heather J; Kuritzkes Daniel R; Gulick Roy M
A comparison of three initial antiretroviral AIDS regimens.
The New England journal of medicine 2007;357(10):1056-7.
-
2007: Johnson Victoria A; Brun-Vézinet Françoise; Clotet Bonaventura; Günthard Huldrych F; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Richman Douglas D
Update of the drug resistance mutations in HIV-1: 2007.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2007;15(4):119-25.
-
2007: Reynes Jacques; Arastéh Keikawus; Clotet Bonaventura; Cohen Calvin; Cooper David A; Delfraissy Jean-François; Eron Joseph J; Henry Keith; Katlama Christine; Kuritzkes Daniel R; Lalezari Jacob P; Lange Joep; Lazzarin Adriano; Montaner Julio S G; Nelson Mark; O' Hearn Mary; Stellbrink Hans-Jürgen; Trottier Benoit; Walmsley Sharon L; Buss Neil E; Demasi Ralph; Chung Jain; Donatacci Lucille; Guimaraes Denise; Rowell Lucy; Valentine Adeline; Wilkinson Martin; Salgo Miklos P
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
-
2007: Kuritzkes Daniel R
Report from the XVI International HIV Drug Resistance Workshop.
AIDS clinical care 2007;19(8):69-70.
-
2007: Hu Zixin; Hatano Hiroyu; Hammond Sarah P; Smith Danielle; Wild Mary; Gupta Soumi; Whitcomb Jeannette; Kalayjian Robert C; Gripshover Barbara; Kuritzkes Daniel R
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Journal of acquired immune deficiency syndromes (1999) 2007;45(5):494-500.
-
2007: Gulick Roy M; Su Zhaohui; Flexner Charles; Hughes Michael D; Skolnik Paul R; Wilkin Timothy J; Gross Robert; Krambrink Amy; Coakley Eoin; Greaves Wayne L; Zolopa Andrew; Reichman Richard; Godfrey Catherine; Hirsch Martin; Kuritzkes Daniel R;
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
The Journal of infectious diseases 2007;196(2):304-12.
-
2007: Gulick Roy M; Lalama Christina M; Ribaudo Heather J; Shikuma Cecilia M; Schackman Bruce R; Schouten Jeffrey; Squires Kathleen E; Koletar Susan L; Pilcher Christopher D; Reichman Richard C; Klingman Karin L; Kuritzkes Daniel R
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
AIDS (London, England) 2007;21(7):813-23.
-
2007: Kuritzkes Daniel R; Ribaudo Heather J; Squires Kathleen E; Koletar Susan L; Santana Jorge; Riddler Sharon A; Reichman Richard; Shikuma Cecilia; Meyer William A; Klingman Karin L; Gulick Roy M;
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
The Journal of infectious diseases 2007;195(8):1169-76.
-
2007: Shikuma Cecilia M; Yang Yang; Glesby Marshall J; Meyer William A; Tashima Karen T; Ribaudo Heather J; Webb Nancy; Bastow Barbara; Kuritzkes Daniel R; Gulick Roy M
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Journal of acquired immune deficiency syndromes (1999) 2007;44(5):540-50.
-
2007: Wilkin Timothy J; Su Zhaohui; Kuritzkes Daniel R; Hughes Michael; Flexner Charles; Gross Robert; Coakley Eoin; Greaves Wayne; Godfrey Catherine; Skolnik Paul R; Timpone Joseph; Rodriguez Benigno; Gulick Roy M
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(4):591-5.
-
2007: Deeks Steven G; Lu Jing; Hoh Rebecca; Neilands Torsten B; Beatty George; Huang Wei; Liegler Teri; Hunt Peter; Martin Jeffrey N; Kuritzkes Daniel R
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
The Journal of infectious diseases 2007;195(3):387-91.
-
2007: Shafer Robert W; Rhee Soo-Yon; Pillay Deenan; Miller Veronica; Sandstrom Paul; Schapiro Jonathan M; Kuritzkes Daniel R; Bennett Diane
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.
AIDS (London, England) 2007;21(2):215-23.
-
2007: Moore Jeff D; Acosta Edward P; Johnson Victoria A; Bassett Roland; Eron Joseph J; Fischl Margaret A; Long Mary C; Kuritzkes Daniel R; Sommadossi Jean-Pierre
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Antiviral therapy 2007;12(6):981-6.
-
2007: Riddler Sharon A; Jiang Hongyu; Tenorio Allan; Huang Hairong; Kuritzkes Daniel R; Acosta Edward P; Landay Alan; Bastow Barbara; Haas David W; Tashima Karen T; Jain Mamta K; Deeks Steven G; Bartlett John A
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.
Antiviral therapy 2007;12(4):531-41.
-
2007: Tsibris Athe M N; Kuritzkes Daniel R
Chemokine antagonists as therapeutics: focus on HIV-1.
Annual review of medicine 2007;58():445-59.
-
2006: Kitchen Christina M R; Lu Jing; Suchard Marc A; Hoh Rebecca; Martin Jeffrey N; Kuritzkes Daniel R; Deeks Steven G
Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.
AIDS research and human retroviruses 2006;22(12):1260-6.
-
2006: De Gruttola Victor; Flexner Charles; Schapiro Jonathan; Hughes Michael; Van Der Laan Mark; Kuritzkes Daniel R
Drug development strategies for salvage therapy: conflicts and solutions.
AIDS research and human retroviruses 2006;22(11):1106-9.
-
2006: Plank Rebeca M; Kuritzkes Daniel R
An update on HIV-1 antiretroviral resistance.
Current opinion in HIV and AIDS 2006;1(5):417-23.
-
2006: Kuritzkes Daniel R
Report from the XV International HIV Drug Resistance Workshop.
AIDS clinical care 2006;18(9):83-4.
-
2006: Marcial Michelle; Lu Jing; Deeks Steven G; Ziermann Rainer; Kuritzkes Daniel R
Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
Journal of clinical microbiology 2006;44(9):3384-7.
-
2006: Lu Jing; Deeks Steven G; Hoh Rebecca; Beatty George; Kuritzkes Benjamin A; Martin Jeffrey N; Kuritzkes Daniel R
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.
Journal of acquired immune deficiency syndromes (1999) 2006;43(1):60-4.
-
2006: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Richman Douglas D
Update of the drug resistance mutations in HIV-1: Fall 2006.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):125-30.
-
2006: Gulick Roy M; Ribaudo Heather J; Shikuma Cecilia M; Lalama Christina; Schackman Bruce R; Meyer William A; Acosta Edward P; Schouten Jeffrey; Squires Kathleen E; Pilcher Christopher D; Murphy Robert L; Koletar Susan L; Carlson Margrit; Reichman Richard C; Bastow Barbara; Klingman Karin L; Kuritzkes Daniel R;
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2006;296(7):769-81.
-
2006: Wu Hulin; Huang Yangxin; Acosta Edward P; Park Jeong-Gun; Yu Song; Rosenkranz Susan L; Kuritzkes Daniel R; Eron Joseph J; Perelson Alan S; Gerber John G
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.
Journal of pharmacokinetics and pharmacodynamics 2006;33(4):399-419.
-
2006: Halvas Elias K; Aldrovandi Grace M; Balfe Peter; Beck Ingrid A; Boltz Valerie F; Coffin John M; Frenkel Lisa M; Hazelwood J Darren; Johnson Victoria A; Kearney Mary; Kovacs Andrea; Kuritzkes Daniel R; Metzner Karin J; Nissley Dwight V; Nowicki Marek; Palmer Sarah; Ziermann Rainer; Zhao Richard Y; Jennings Cheryl L; Bremer James; Brambilla Don; Mellors John W
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
Journal of clinical microbiology 2006;44(7):2612-4.
-
2006: Hu Zixin; Giguel Françoise; Hatano Hiroyu; Reid Patrick; Lu Jing; Kuritzkes Daniel R
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
Journal of virology 2006;80(14):7020-7.
-
2006: Koenig Serena P; Kuritzkes Daniel R; Hirsch Martin S; Léandre Fernet; Mukherjee Joia S; Farmer Paul E; del Rio Carlos
Monitoring HIV treatment in developing countries.
BMJ (Clinical research ed.) 2006;332(7541):602-4.
-
2006: Ribaudo Heather J; Haas David W; Tierney Camlin; Kim Richard B; Wilkinson Grant R; Gulick Roy M; Clifford David B; Marzolini Catia; Fletcher Courtney V; Tashima Karen T; Kuritzkes Daniel R; Acosta Edward P;
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(3):401-7.
-
2006: Ribaudo Heather J; Kuritzkes Daniel R; Schackman Bruce R; Acosta Edward P; Shikuma Cecilia M; Gulick Roy M
Design issues in initial HIV-treatment trials: focus on ACTG A5095.
Antiviral therapy 2006;11(6):751-60.
-
2006: Gripshover Barbara M; Ribaudo Heather; Santana Jorge; Gerber John G; Campbell Thomas B; Hogg Evelyn; Jarocki Bernadette; Hammer Scott M; Kuritzkes Daniel R;
Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).
Antiviral therapy 2006;11(5):619-23.
-
2005: Nelson Mark; Arastéh Keikawus; Clotet Bonaventura; Cooper David A; Henry Keith; Katlama Christine; Lalezari Jacob P; Lazzarin Adriano; Montaner Julio S G; O'Hearn Mary; Piliero Peter J; Reynes Jacques; Trottier Benoit; Walmsley Sharon L; Cohen Calvin; Eron Joseph J; Kuritzkes Daniel R; Lange Joep; Stellbrink Hans-Jürgen; Delfraissy Jean-François; Buss Neil E; Donatacci Lucille; Wat Cynthia; Smiley Lynn; Wilkinson Martin; Valentine Adeline; Guimaraes Denise; Demasi Ralph; Chung Jain; Salgo Miklos P
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
-
2005: Kuritzkes Daniel R
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
The Journal of infectious diseases 2005;192(11):1867-8.
-
2005: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Telenti Amalio; Richman Douglas D
Update of the drug resistance mutations in HIV-1: Fall 2005.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(4):125-31.
-
2005: Lu Jing; Whitcomb Jeannette; Kuritzkes Daniel R
Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.
Journal of acquired immune deficiency syndromes (1999) 2005;40(1):20-3.
-
2005: Campbell Thomas B; Shulman Nancy S; Johnson Steven C; Zolopa Andrew R; Young Russell K; Bushman Lane; Fletcher Courtney V; Lanier E Randall; Merigan Thomas C; Kuritzkes Daniel R
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(2):236-42.
-
2005: Wu Hulin; Huang Yangxin; Acosta Edward P; Rosenkranz Susan L; Kuritzkes Daniel R; Eron Joseph J; Perelson Alan S; Gerber John G
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance.
Journal of acquired immune deficiency syndromes (1999) 2005;39(3):272-83.
-
2005: Miranda Luis R; Götte Matthias; Liang Fei; Kuritzkes Daniel R
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Antimicrobial agents and chemotherapy 2005;49(7):2648-56.
-
2005: Zolopa Andrew R; Lazzeroni Laura C; Rinehart Alex; Vezinet Françoise Brun; Clavel François; Collier Ann; Conway Brian; Gulick Roy M; Holodniy Mark; Perno Carlo-Frederico; Shafer Robert W; Richman Douglas D; Wainberg Mark A; Kuritzkes Daniel R
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(1):92-9.
-
2005: Cohan Deborah; Feakins Cynthia; Wara Diane; Petru Ann; McNicholl Ian; Schillinger Dean; Lu Jing; Kuritzkes Daniel; Deeks Steven G
Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.
AIDS (London, England) 2005;19(9):989-90.
-
2005: Sharkey Mark; Triques Karine; Kuritzkes Daniel R; Stevenson Mario
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.
Journal of virology 2005;79(8):5203-10.
-
2005: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan; Telenti Amalio; Richman Douglas
Update of the Drug Resistance Mutations in HIV-1: 2005.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(1):51-7.
-
2005: Wainberg Mark A; Sawyer James P C; Montaner Julio S G; Murphy Robert L; Kuritzkes Daniel R; Raffi Francois
Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Antiviral therapy 2005;10(1):13-28.
-
2004: Eron Joseph J; Bartlett John A; Santana Jorge L; Bellos Nicholas C; Johnson Judy; Keller Amy; Kuritzkes Daniel R; St Clair Marty H; Johnson Victoria A
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.
Journal of acquired immune deficiency syndromes (1999) 2004;37(5):1581-3.
-
2004: Kuritzkes Daniel R
Quantification of human immunodeficiency virus type 1 by reverse transcriptase-coupled polymerase chain reaction.
The Journal of infectious diseases 2004;190(11):2047-54.
-
2004: Acosta Edward P; Wu Hulin; Hammer Scott M; Yu Song; Kuritzkes Daniel R; Walawander Ann; Eron Joseph J; Fichtenbaum Carl J; Pettinelli Carla; Neath Denise; Ferguson Elaine; Saah Alfred J; Gerber John G;
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2004;37(3):1358-66.
-
2004: Johnson Victoria A; Brun-Vézinet Francoise; Clotet Bonaventura; Conway Brian; D'Aquila Richard T; Demeter Lisa M; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Telenti Amalio; Richman Douglas D
Update of the drug resistance mutations in HIV-1: 2004.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2004;12(4):119-24.
-
2004: Youle Mike; Cohen Cal; Katlama Christine; Kuritzkes Dan; Walmsley Sharon
Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.
Lancet 2004;364(9439):1036-7.
-
2004: Smith Kimberly; Aga Evgenia; Bosch Ronald J; Valdez Hernan; Connick Elizabeth; Landay Alan; Kuritzkes Daniel; Gross Barry H; Francis Isaac R; McCune Joseph M; Kessler Harold; Lederman Michael
Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy.
AIDS (London, England) 2004;18(14):1953-6.
-
2004: Brun-Vézinet Françoise; Costagliola Dominique; Khaled Mounir Ait; Calvez Vincent; Clavel François; Clotet Bonaventura; Haubrich Richard; Kempf Dale; King Marty; Kuritzkes Daniel; Lanier Randall; Miller Michael; Miller Veronica; Phillips Andrews; Pillay Deenan; Schapiro Jonathan; Scott Janna; Shafer Robert; Zazzi Maurizio; Zolopa Andrew; DeGruttola Victor
Clinically validated genotype analysis: guiding principles and statistical concerns.
Antiviral therapy 2004;9(4):465-78.
-
2004: Kuritzkes Daniel R
When more is less.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(4):559-60.
-
2004: Campbell Thomas B; Rapaport Eric; Schooley Robert T; Kuritzkes Daniel R
Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim.
The Journal of infectious diseases 2004;190(2):257-66.
-
2004: Lange Joep M A; Perriens Jos; Kuritzkes Dan; Zewdie Debrework
What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection.
AIDS (London, England) 2004;18 Suppl 3():S69-74.
-
2004: Kuritzkes Daniel R
Extending antiretroviral therapy to resource-poor settings: implications for drug resistance.
AIDS (London, England) 2004;18 Suppl 3():S45-8.
-
2004: Zewdie Debrework; Lange Joep; Kuritzkes Daniel
Rapid expansion of access to antiretroviral therapy (ART).
AIDS (London, England) 2004;18 Suppl 3():S1-3.
-
2004: Kuritzkes Daniel R
Preventing and managing antiretroviral drug resistance.
AIDS patient care and STDs 2004;18(5):259-73.
-
2004: Mildvan Donna; Bosch Ronald J; Kim Ryung S; Spritzler John; Haas David W; Kuritzkes Daniel; Kagan Jonathan; Nokta Mostafa; DeGruttola Victor; Moreno Melanie; Landay Alan
Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.
The Journal of infectious diseases 2004;189(10):1811-20.
-
2004: Kuritzkes Daniel R; Bassett Roland L; Hazelwood J Darren; Barrett Heidi; Rhodes Ruth A; Young Russell K; Johnson Victoria A;
Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.
Journal of acquired immune deficiency syndromes (1999) 2004;36(1):600-3.
-
2004: Lu Jing; Sista Prakash; Giguel Françoise; Greenberg Michael; Kuritzkes Daniel R
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
Journal of virology 2004;78(9):4628-37.
-
2004: Gulick Roy M; Ribaudo Heather J; Shikuma Cecilia M; Lustgarten Stephanie; Squires Kathleen E; Meyer William A; Acosta Edward P; Schackman Bruce R; Pilcher Christopher D; Murphy Robert L; Maher William E; Witt Mallory D; Reichman Richard C; Snyder Sally; Klingman Karin L; Kuritzkes Daniel R;
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
The New England journal of medicine 2004;350(18):1850-61.
-
2004: Kuritzkes Daniel R
Ethical conduct of research in resource-limited settings.
The Journal of infectious diseases 2004;189(5):764-5.
-
2004: Kuritzkes Daniel R; Jacobson Jeffrey; Powderly William G; Godofsky Eliot; DeJesus Edwin; Haas Frances; Reimann Keith A; Larson Jeffrey L; Yarbough Patrice O; Curt Valentin; Shanahan William R
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.
The Journal of infectious diseases 2004;189(2):286-91.
-
2003: Tenorio Allan R; Smith Kimberly Y; Kuritzkes Daniel R; Sha Beverly E; Donoval Betty; Young Russell; Jennings Cheryl; Bremer James; Shott Susan; Landay Alan; Kessler Harold A
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course.
Journal of acquired immune deficiency syndromes (1999) 2003;34(5):491-6.
-
2003: Johnson Victoria A; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; D'Aquila Richard T; Demeter Lisa M; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Telenti Amalio; Richman Douglas D;
Drug resistance mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(6):215-21.
-
2003: Landay Alan L; Spritzler John; Kessler Harold; Mildvan Donna; Pu Minya; Fox Larry; O'Neil Dorothy; Schock Barbara; Kuritzkes Daniel; Lederman Michael M;
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen.
The Journal of infectious diseases 2003;188(10):1444-54.
-
2003: Haas David W; Wu Hulin; Li Haihong; Bosch Ronald J; Lederman Michael M; Kuritzkes Daniel; Landay Alan; Connick Elizabeth; Benson Constance; Wilkinson Grant R; Kessler Harold; Kim Richard B
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.
Journal of acquired immune deficiency syndromes (1999) 2003;34(3):295-8.
-
2003: Kuritzkes Daniel; Lange Joep; Zewdie Debrework
World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries.
Nature medicine 2003;9(11):1343-4.
-
2003: Kuritzkes Daniel R
Preventing and managing resistance in the clinical setting.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 2():S103-10.
-
2003: Jiang Hongyu; Deeks Steven G; Kuritzkes Daniel R; Lallemant Marc; Katzenstein David; Albrecht Mary; DeGruttola Victor
Assessing resistance costs of antiretroviral therapies via measures of future drug options.
The Journal of infectious diseases 2003;188(7):1001-8.
-
2003: Haas David W; Wilkinson Grant R; Kuritzkes Daniel R; Richman Douglas D; Nicotera Janet; Mahon Laura F; Sutcliffe Cara; Siminski Sue; Andersen Janet; Coughlin Kristine; Clayton Ellen W; Haines Jonathan; Marshak Ann; Saag Michael; Lawrence Jody; Gustavson Jeffrey; Anne Bennett Jo; Christensen Rolf; Matula Margaret A; Wood Alastair J J;
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128.
HIV clinical trials 2003;4(5):287-300.
-
2003: Bartlett John A; Tebas Pablo; Bassett Roland; Huang Wenzheng; Kuritzkes Daniel; Reisler Ronald; Loyack Nancy; Robison Kellye;
Early intensification with abacavir in subjects at high risk for incomplete viral suppression.
Antiviral therapy 2003;8(4):361-3.
-
2003: Weber Jan; Rangel Hector R; Chakraborty Bikram; Marotta Michael L; Valdez Hernan; Fransen Katrien; Florence Eric; Connick Elizabeth; Smith Kimberly Y; Colebunders Robert L; Landay Alan; Kuritzkes Daniel R; Lederman Michael M; Vanham Guido; Quiñones-Mateu Miguel E
Role of Baseline pol Genotype in HIV-1 Fitness Evolution.
Journal of acquired immune deficiency syndromes (1999) 2003;33(4):448-60.
-
2003: Hirsch Martin S; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; D'Aquila Richard T; Demeter Lisa M; Hammer Scott M; Johnson Victoria A; Loveday Clive; Mellors John W; Richman Douglas D;
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(4):150-4.
-
2003: Kosmiski L; Kuritzkes D; Hamilton J; Sharp T; Lichtenstien K; Hill J; Eckel R
Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome.
HIV medicine 2003;4(3):235-40.
-
2003: Hirsch Martin S; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; D'Aquila Richard T; Demeter Lisa M; Hammer Scott M; Johnson Victoria A; Loveday Clive; Mellors John W; Jacobsen Donna M; Richman Douglas D
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(1):113-28.
-
2003: Kuritzkes Daniel R
Management of patients with virologic and metabolic failure.
The AIDS reader 2003;13(6 Suppl):S17-22.
-
2003: D'Aquila Richard T; Schapiro Jonathan M; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; Demeter Lisa M; Grant Robert M; Johnson Victoria A; Kuritzkes Daniel R; Loveday Clive; Shafer Robert W; Richman Douglas D
Drug resistance mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(3):92-6.
-
2003: Kosmiski Lisa A; Kuritzkes Daniel R; Sharp Teresa A; Hamilton Jere T; Lichtenstein Kenneth A; Mosca Cecilia L; Grunwald Gary K; Eckel Robert H; Hill James O
Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.
Metabolism: clinical and experimental 2003;52(5):620-5.
-
2003: Lalezari Jacob P; Henry Keith; O'Hearn Mary; Montaner Julio S G; Piliero Peter J; Trottier Benôit; Walmsley Sharon; Cohen Calvin; Kuritzkes Daniel R; Eron Joseph J; Chung Jain; DeMasi Ralph; Donatacci Lucille; Drobnes Claude; Delehanty John; Salgo Miklos;
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
The New England journal of medicine 2003;348(22):2175-85.
-
2003: Kuritzkes Daniel R
HIV/AIDS salvage therapy. Interview by Vicki Glaser.
AIDS patient care and STDs 2003;17(4):141-5.
-
2003: Kuritzkes Daniel R; Grant Robert M; Feorino Paul; Griswold Marshal; Hoover Marie; Young Russell; Day Stephen; Lloyd Jr Robert M; Reid Caroline; Morgan Gillian F; Winslow Dean L
Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.
Journal of clinical microbiology 2003;41(4):1594-9.
-
2003: Grant Robert M; Kuritzkes Daniel R; Johnson Victoria A; Mellors John W; Sullivan John L; Swanstrom Ronald; D'Aquila Richard T; Van Gorder Mark; Holodniy Mark; Lloyd Jr Robert M; Reid Caroline; Morgan Gillian F; Winslow Dean L
Accuracy of the TRUGENE HIV-1 genotyping kit.
Journal of clinical microbiology 2003;41(4):1586-93.
-
2003: Kuritzkes Daniel R; Boyle Brian A; Gallant Joel E; Squires Kathleen E; Zolopa Andrew
Current management challenges in HIV: antiretroviral resistance.
The AIDS reader 2003;13(3):133-5, 138-42.
-
2003: Kosmiski Lisa; Kuritzkes Daniel; Lichtenstein Kenneth; Eckel Robert
Adipocyte-derived hormone levels in HIV lipodystrophy.
Antiviral therapy 2003;8(1):9-15.
-
2003: Kuritzkes Daniel R; Currier Judith
Cardiovascular risk factors and antiretroviral therapy.
The New England journal of medicine 2003;348(8):679-80.
-
2002: Stoeckli Thomas C; MaWhinney Samantha; Uy Jonathan; Duan Chengying; Lu Jing; Shugarts David; Kuritzkes Daniel R
Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
Antimicrobial agents and chemotherapy 2002;46(12):4000-3.
-
2002: Kuritzkes Daniel R
Resistance to protease inhibitors.
Journal of HIV therapy 2002;7(4):87-91.
-
2002: Skowron Gail; Kuritzkes Daniel R; Thompson Melanie A; Squires Kathleen E; Goodwin S Diane; Dusak Betsy A; Tolson Jerry M; Stevens Michael; Yuen Geoffrey J; Rooney James F;
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
The Journal of infectious diseases 2002;186(7):1028-33.
-
2002: Ickovics Jeonnette R; Cameron Ann; Zackin Robert; Bassett Roland; Chesney Margaret; Johnson Victoria A; Kuritzkes Daniel R;
Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.
Antiviral therapy 2002;7(3):185-93.
-
2002: Kuritzkes Daniel
Drug resistance. Navigating resistance pathways.
The AIDS reader 2002;12(9):395-400, 407.
-
2002: Valdez Hernan; Connick Elizabeth; Smith Kimberly Y; Lederman Michael M; Bosch Ronald J; Kim Ryung S; St Clair Marty; Kuritzkes Daniel R; Kessler Harold; Fox Lawrence; Blanchard-Vargas Michelle; Landay Alan;
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease.
AIDS (London, England) 2002;16(14):1859-66.
-
2002: McFarland Elizabeth J; Harding Paul A; Striebich Christopher C; MaWhinney Samantha; Kuritzkes Daniel R; Kotzin Brian L
Clonal CD8+ T cell expansions in peripheral blood from human immunodeficiency virus type 1-infected children.
The Journal of infectious diseases 2002;186(4):477-85.
-
2001: Connick E; Schlichtemeier R L; Purner M B; Schneider K M; Anderson D M; MaWhinney S; Campbell T B; Kuritzkes D R; Douglas J M; Judson F N; Schooley R T
Relationship between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T lymphocytes and virus load after recent HIV-1 seroconversion.
The Journal of infectious diseases 2001;184(11):1465-9.
-
2001: Kuritzkes D R
A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(24):13485-7.
-
2001: Duan C; Poticha D; Stoeckli T C; Petropoulos C J; Whitcomb J M; McHenry C S; Kuritzkes D R
Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
The Journal of infectious diseases 2001;184(10):1336-40.
-
2001: Kosmiski L A; Kuritzkes D R; Lichtenstein K A; Glueck D H; Gourley P J; Stamm E R; Scherzinger A L; Eckel R H
Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.
AIDS (London, England) 2001;15(15):1993-2000.
-
2001: Lu J; Kuritzkes D R
A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants.
Journal of acquired immune deficiency syndromes (1999) 2001;27(1):7-13.
-
2001: Stubbs A C; Martin K S; Coeshott C; Skaates S V; Kuritzkes D R; Bellgrau D; Franzusoff A; Duke R C; Wilson C C
Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity.
Nature medicine 2001;7(5):625-9.
-
2001: Gulick R M; Smeaton L M; D'Aquila R T; Eron J J; Currier J S; Gerber J G; Acosta E; Sommadossi J P; Tung R; Snyder S; Kuritzkes D R; Murphy R L;
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
The Journal of infectious diseases 2001;183(5):715-21.
-
2001: Gilbert P B; DeGruttola V; Hammer S M; Kuritzkes D R
Virologic and regimen termination surrogate end points in AIDS clinical trials.
JAMA : the journal of the American Medical Association 2001;285(6):777-84.
-
2000: Schooley R T; Spino C; Kuritzkes D; Walker B D; Valentine F A; Hirsch M S; Cooney E; Friedland G; Kundu S; Merigan T C; McElrath M J; Collier A; Plaeger S; Mitsuyasu R; Kahn J; Haslett P; Uherova P; deGruttola V; Chiu S; Zhang B; Jones G; Bell D; Ketter N; Twadell T; Chernoff D; Rosandich M
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
The Journal of infectious diseases 2000;182(5):1357-64.
-
2000: Gilbert P B; Hanna G J; De Gruttola V; Martinez-Picado J; Kuritzkes D R; Johnson V A; Richman D D; D'Aquila R T
Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens.
AIDS research and human retroviruses 2000;16(14):1325-36.
-
2000: Gilbert P B; Ribaudo H J; Greenberg L; Yu G; Bosch R J; Tierney C; Kuritzkes D R
Considerations in choosing a primary endpoint that measures durability of virological suppression in an antiretroviral trial.
AIDS (London, England) 2000;14(13):1961-72.
-
2000: Kuritzkes D R; Bassett R L; Johnson V A; Marschner I C; Eron J J; Sommadossi J P; Acosta E P; Murphy R L; Fife K; Wood K; Bell D; Martinez A; Pettinelli C B
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
AIDS (London, England) 2000;14(11):1553-61.
-
2000: Hanna G J; Johnson V A; Kuritzkes D R; Richman D D; Martinez-Picado J; Sutton L; Hazelwood J D; D'Aquila R T
Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.
Journal of clinical microbiology 2000;38(7):2715-21.
-
2000: Hirsch M S; Brun-Vézinet F; D'Aquila R T; Hammer S M; Johnson V A; Kuritzkes D R; Loveday C; Mellors J W; Clotet B; Conway B; Demeter L M; Vella S; Jacobsen D M; Richman D D
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(18):2417-26.
-
2000: Hanna G J; Johnson V A; Kuritzkes D R; Richman D D; Brown A J; Savara A V; Hazelwood J D; D'Aquila R T
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
The Journal of infectious diseases 2000;181(3):904-11.
-
2000: Kuritzkes D R
Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30(2):256-60.
-
2000: Kuritzkes D R; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman M M
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
The Journal of infectious diseases 2000;181(2):491-7.
-
2000: Valdez H; Smith K Y; Landay A; Connick E; Kuritzkes D R; Kessler H; Fox L; Spritzler J; Roe J; Lederman M B; Lederman H M; Evans T G; Heath-Chiozzi M; Lederman M M
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group.
AIDS (London, England) 2000;14(1):11-21.
-
2000: Kuritzkes D R; Shugarts D; Bakhtiari M; Poticha D; Johnson J; Rubin M; Gingeras T R; Kennedy M; Eron J J
Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
Journal of acquired immune deficiency syndromes (1999) 2000;23(1):26-34.
-
2000: Connick E; Lederman M M; Kotzin B L; Spritzler J; Kuritzkes D R; St Clair M; Sevin A D; Fox L; Chiozzi M H; Leonard J M; Rousseau F; D'Arc Roe J; Martinez A; Kessler H; Landay A
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
The Journal of infectious diseases 2000;181(1):358-63.
-
2000: Smith K Y; Valdez H; Landay A; Spritzler J; Kessler H A; Connick E; Kuritzkes D; Gross B; Francis I; McCune J M; Lederman M M
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.
The Journal of infectious diseases 2000;181(1):141-7.
-
2000: Campbell T B; Sevin A; Coombs R W; Peterson G C; Rosandich M; Kuritzkes D R; Mladenovic J; Landay A; Wong R; Ambruso D; Miles S; Pomerantz R J; Schooley R T
Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team.
Blood 2000;95(1):48-55.
-
1999: Young B; Kuritzkes D R
Viral kinetics: implications for treatment.
AIDS (London, England) 1999;13 Suppl 1():S11-7.
-
1999: Patki A H; Purvis S F; Valdez H; Spritzler J; Connick E; Kuritzkes D R; Kessler H; Fox L; St Clair M; Landay A; Lederman M M
HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication.
AIDS (London, England) 1999;13(10):1177-85.
-
1999: Kuritzkes D R; Marschner I; Johnson V A; Bassett R; Eron J J; Fischl M A; Murphy R L; Fife K; Maenza J; Rosandich M E; Bell D; Wood K; Sommadossi J P; Pettinelli C
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
AIDS (London, England) 1999;13(6):685-94.
-
1999: Murphy R L; Gulick R M; DeGruttola V; D'Aquila R T; Eron J J; Sommadossi J P; Currier J S; Smeaton L; Frank I; Caliendo A M; Gerber J G; Tung R; Kuritzkes D R
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
The Journal of infectious diseases 1999;179(4):808-16.
-
1999: Wu H; Kuritzkes D R; McClernon D R; Kessler H; Connick E; Landay A; Spear G; Heath-Chiozzi M; Rousseau F; Fox L; Spritzler J; Leonard J M; Lederman M M
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.
The Journal of infectious diseases 1999;179(4):799-807.
-
1999: Marschner I C; Betensky R A; DeGruttola V; Hammer S M; Kuritzkes D R
Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1999;20(3):220-7.
-
1999: Kuritzkes D R
Clinical experience with Filgrastim in AIDS.
Journal of hematotherapy & stem cell research 1999;8 Suppl 1():S17-9.
-
1998: Demeter L M; D'Aquila R; Weislow O; Lorenzo E; Erice A; Fitzgibbon J; Shafer R; Richman D; Howard T M; Zhao Y; Fisher E; Huang D; Mayers D; Sylvester S; Arens M; Sannerud K; Rasheed S; Johnson V; Kuritzkes D; Reichelderfer P; Japour A
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.
Journal of virological methods 1998;75(1):93-104.
-
1998: Young B; Johnson S; Bahktiari M; Shugarts D; Young R K; Allen M; Ramey R R; Kuritzkes D R
Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure.
The Journal of infectious diseases 1998;178(5):1497-501.
-
1998: Lederman M M; Connick E; Landay A; Kuritzkes D R; Spritzler J; St Clair M; Kotzin B L; Fox L; Chiozzi M H; Leonard J M; Rousseau F; Wade M; Roe J D; Martinez A; Kessler H
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
The Journal of infectious diseases 1998;178(1):70-9.
-
1998: McFarland E J; Harding P A; MaWhinney S; Schooley R T; Kuritzkes D R
In vitro effects of IL-12 on HIV-1-specific CTL lines from HIV-1-infected children.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(1):513-9.
-
1998: Hirsch M S; Conway B; D'Aquila R T; Johnson V A; Brun-Vézinet F; Clotet B; Demeter L M; Hammer S M; Jacobsen D M; Kuritzkes D R; Loveday C; Mellors J W; Vella S; Richman D D
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
JAMA : the journal of the American Medical Association 1998;279(24):1984-91.
-
1998: Kuritzkes D R; Parenti D; Ward D J; Rachlis A; Wong R J; Mallon K P; Rich W J; Jacobson M A
Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group.
AIDS (London, England) 1998;12(1):65-74.
-
1997: Hughes M D; Johnson V A; Hirsch M S; Bremer J W; Elbeik T; Erice A; Kuritzkes D R; Scott W A; Spector S A; Basgoz N; Fischl M A; D'Aquila R T
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Annals of internal medicine 1997;126(12):929-38.
-
1997: McDonald C K; Kuritzkes D R
Human immunodeficiency virus type 1 protease inhibitors.
Archives of internal medicine 1997;157(9):951-9.
-
1996: Kuritzkes D R
Clinical significance of drug resistance in HIV-1 infection.
AIDS (London, England) 1996;10 Suppl 5():S27-31.
-
1996: Coombs R W; Welles S L; Hooper C; Reichelderfer P S; D'Aquila R T; Japour A J; Johnson V A; Kuritzkes D R; Richman D D; Kwok S; Todd J; Jackson J B; DeGruttola V; Crumpacker C S; Kahn J
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
The Journal of infectious diseases 1996;174(4):704-12.
-
1996: Welles S L; Jackson J B; Yen-Lieberman B; Demeter L; Japour A J; Smeaton L M; Johnson V A; Kuritzkes D R; D'Aquila R T; Reichelderfer P A; Richman D D; Reichman R; Fischl M; Dolin R; Coombs R W; Kahn J O; McLaren C; Todd J; Kwok S; Crumpacker C S
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.
The Journal of infectious diseases 1996;174(4):696-703.
-
1996: Uherova P; Connick E; MaWhinney S; Schlichtemeier R; Schooley R T; Kuritzkes D R
In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1.
The Journal of infectious diseases 1996;174(3):483-9.
-
1996: Kuritzkes D R; Quinn J B; Benoit S L; Shugarts D L; Griffin A; Bakhtiari M; Poticha D; Eron J J; Fallon M A; Rubin M
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
AIDS (London, England) 1996;10(9):975-81.
-
1996: Schooley R T; Campbell T B; Kuritzkes D R; Blaschke T; Stein D S; Rosandich M E; Phair J; Pottage J C; Messari F; Collier A; Kahn J
Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;12(4):363-70.
-
1996: Shafer R W; Winters M A; Mayers D L; Japour A J; Kuritzkes D R; Weislow O S; White F; Erice A; Sannerud K J; Iversen A; Pena F; Dimitrov D; Frenkel L M; Reichelderfer P S
Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group.
Journal of clinical microbiology 1996;34(7):1849-53.
-
1995: Eron J J; Benoit S L; Jemsek J; MacArthur R D; Santana J; Quinn J B; Kuritzkes D R; Fallon M A; Rubin M
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
The New England journal of medicine 1995;333(25):1662-9.
-
1995: Japour A J; Welles S; D'Aquila R T; Johnson V A; Richman D D; Coombs R W; Reichelderfer P S; Kahn J O; Crumpacker C S; Kuritzkes D R
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.
The Journal of infectious diseases 1995;171(5):1172-9.
-
1995: D'Aquila R T; Johnson V A; Welles S L; Japour A J; Kuritzkes D R; DeGruttola V; Reichelderfer P S; Coombs R W; Crumpacker C S; Kahn J O; Richman D D
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
Annals of internal medicine 1995;122(6):401-8.
-
1994: McFarland E J; Harding P A; Luckey D; Conway B; Young R K; Kuritzkes D R
High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 1994;170(4):766-74.
-
1994: Japour A J; Fiscus S A; Arduino J M; Mayers D L; Reichelderfer P S; Kuritzkes D R
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.
Journal of clinical microbiology 1994;32(9):2291-4.
-
1994: Kuritzkes D R; Bell S; Bakhtiari M
Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.
AIDS (London, England) 1994;8(7):1017-9.
-
1993: Campbell T B; Young R K; Eron J J; D'Aquila R T; Tarpley W G; Kuritzkes D R
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
The Journal of infectious diseases 1993;168(2):318-26.
-
1993: Japour A J; Mayers D L; Johnson V A; Kuritzkes D R; Beckett L A; Arduino J M; Lane J; Black R J; Reichelderfer P S; D'Aquila R T
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.
Antimicrobial agents and chemotherapy 1993;37(5):1095-101.
-
1993: McFarland E J; Curiel T J; Schoen D J; Rosandich M E; Schooley R T; Kuritzkes D R
Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type 1 Gag and reverse transcriptase derived from a vertically infected child.
The Journal of infectious diseases 1993;167(3):719-23.
-
1993: McFarland E J; Kuritzkes D R
Clinical features and treatment of infection due to mycobacterium fortuitum/chelonae complex.
Current clinical topics in infectious diseases 1993;13():188-202.
-
1992: Zhang X Q; Yang L; Ho D D; Kuritzkes D R; Chen I S; Ching W T; Chen Y M; Schooley R T
Human T lymphotropic virus types I- and II-specific antibody-dependent cellular cytotoxicity: strain specificity and epitope mapping.
The Journal of infectious diseases 1992;165(5):805-12.
Sign-in to see more
